Experimental cancer drug offered to patients with no other options
NCT ID NCT05982873
Summary
This program provides early access to an investigational cancer drug called telisotuzumab adizutecan for people with solid tumors. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trials. A doctor must determine if the potential benefit for the individual patient outweighs the risks of receiving a therapy not yet fully approved.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.